Smart Nanoparticles Deliver mRNA Directly to Tumors in New Cancer Therapy

A team of researchers at the University of Adelaide has developed a new method using smart nanoparticles to deliver messenger RNA directly into tumors, effectively reprogramming the surrounding immune environment. The findings, reported by Wired on September 16, 2026, and published in Science Advances on September 11, 2026, demonstrate a significant proof of concept in mice with aggressive breast cancer.

What is the mechanism behind this nanoparticle therapy?

The treatment targets tumor-associated macrophages (TAMs), which are white blood cells found inside tumors that cancer cells typically reprogram to suppress the immune system. Once tumors form, they create an oppressive microenvironment that declaws cancer-fighting immune cells and prevents T-cells from entering or doing their jobs. By utilizing nanoparticle technology to encapsulate and deliver mRNA directly to these macrophages, the University of Adelaide team aimed to change that environment from within.

According to Wired and Medical Xpress reports, the treatment yielded distinct biological changes in mice after three doses:

• NOS2 expression increased by a factor of 89.5.
• Tumor CXCL9 concentration was approximately four times higher than in the control group.
• The proportion of macrophages with immunosuppressive characteristics dropped by 63 percent.

“Our approach is designed to change that environment from within the tumor,” University of Adelaide Professor Chunxia Zhao said, according to Medical Xpress. “By specifically targeting tumor-associated macrophages, we can deliver the treatment where it is needed and encourage the immune system's cancer-fighting T cells to enter the tumor and become more active.”

How did the treatment perform alongside checkpoint blockers?

When researchers combined the nanoparticle mRNA therapy with immune checkpoint-blocking drugs such as PD-L1 and CTLA-4, the results showed notable immune shifts without immediate extra shrinkage. Wired, Medical Xpress, and Bioengineer.org reported that while the combination generated important changes in the immune system—including an increase in cancer-fighting T cells and central memory T cells—it did not produce additional tumor-growth inhibition in this particular mouse model.

“This is an important proof of concept that we can use mRNA and nanoparticle technology to reprogram the immune environment of a tumor,” Professor Zhao stated, as noted by Wired and Bioengineer.org.

When will human trials begin?

Specific timelines or dates for human clinical trials have not yet been announced or confirmed. Professor Zhao and collaborating institutions—including SA Pathology and the Royal Adelaide Hospital—noted that significant work remains to evaluate safety parameters and determine effectiveness before the approach could be considered for patients.